[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
About Journal::
Editorial Board::
Articles Archive::
Indexing Databases::
To Authors::
To Reviewers::
Registration::
Submit Your Article::
Policies and Publication Ethics::
Archiving Policy::
Site Facilities::
Contact Us::
::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019
Citations720581
h-index1110
i10-index1512
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Registered in

AWT IMAGE

AWT IMAGE

..
:: Volume 8, Issue 4 (9-2021) ::
2021, 8(4): 1-12 Back to browse issues page
Effects of harmalol on scopolamine-induced memory disorders, anxiety and depression like behaviors in male mice: A behavioral and molecular study
Mahbubeh Setorki
Department of Biology, Izeh Branch, Islamic Azad University, Izeh, Iran , doctor.setorgi@gmail.com
Abstract:   (1893 Views)
Introduction: Harmalol is a dihydrocarboline compound found naturally in several alcoholic beverages and medicinal plants. This study was designed to investigate the effect of harmalol on memory function and its possible mechanisms in a scopolamine-induced memory disorder model.
Materials and Methods: Thirty five male mice were randomly divided into five (n=7) group: Control group )normal saline(, scopolamin   group (scopolamine at a dose of 1 mg / kg)  and treatment groups (harmalol in three doses of 5, 10 and 20 mg / kg with scopolamine) for 21 days.  Behavioral tests were performed after the treatment period. The mice were then subjected to deep anesthesia and blood and brain tissue samples were obtained.
Results: Harmalol significantly decreased latency to reach the hidden platform in spatial memory test and secondary latency in passive avoidance memory test and immobility time in the forced swimming test compared to scopolamine group (P < 0.05). This compound, at the dose of 20 mg/kg, showed a significant increase in the number of crossing and standing on two legs in open field test (P < 0.05). Furthermore, harmalol treatment decreased brain malondialdehyde and nitric oxide  levels, enhanced the total antioxidant capacity, and also increased the level of brain-derived neurotrophic factor (BDNF)  in the hippocampus (P < 0.05).
Conclusion: The present study emphasizes that harmalol improves scopolamine-induced memory loss by modulating acetylcholinesterase activity and increasing BDNF in the hippocampus of  mice. Therefore, harmalol may be a promising therapeutic drug to prevent amnesia and cognitive deficits associated with aging or neurodegenerative diseases such as Alzheimer's.
Introduction: Harmalol is a dihydrocarboline compound found naturally in several alcoholic beverages and medicinal plants. This study was designed to investigate the effect of harmalol on memory function and its possible mechanisms in a scopolamine-induced memory disorder model.
Materials and Methods: Thirty five male mice were randomly divided into five (n=7) group: Control group )normal saline(, scopolamin   group (scopolamine at a dose of 1 mg / kg)  and treatment groups (harmalol in three doses of 5, 10 and 20 mg / kg with scopolamine) for 21 days.  Behavioral tests were performed after the treatment period. The mice were then subjected to deep anesthesia and blood and brain tissue samples were obtained.
Results: Harmalol significantly decreased latency to reach the hidden platform in spatial memory test and secondary latency in passive avoidance memory test and immobility time in the forced swimming test compared to scopolamine group (P < 0.05). This compound, at the dose of 20 mg/kg, showed a significant increase in the number of crossing and standing on two legs in open field test (P < 0.05). Furthermore, harmalol treatment decreased brain malondialdehyde and nitric oxide  levels, enhanced the total antioxidant capacity, and also increased the level of brain-derived neurotrophic factor (BDNF)  in the hippocampus (P < 0.05).
Conclusion: The present study emphasizes that harmalol improves scopolamine-induced memory loss by modulating acetylcholinesterase activity and increasing BDNF in the hippocampus of  mice. Therefore, harmalol may be a promising therapeutic drug to prevent amnesia and cognitive deficits associated with aging or neurodegenerative diseases such as Alzheimer's.
Keywords: Scopolamine, Harmalol, Memory deficits, Mice
Full-Text [PDF 1002 kb]   (592 Downloads)    
Type of Study: Research | Subject: Physiology
Received: 2020/11/9 | Accepted: 2021/02/19 | Published: 2021/09/19
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Setorki M. Effects of harmalol on scopolamine-induced memory disorders, anxiety and depression like behaviors in male mice: A behavioral and molecular study. Journal of Basic Research in Medical Sciences 2021; 8 (4) :1-12
URL: http://jbrms.medilam.ac.ir/article-1-590-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 8, Issue 4 (9-2021) Back to browse issues page
مجله ی تحقیقات پایه در علوم پزشکی Journal of Basic Research in Medical Sciences
Persian site map - English site map - Created in 0.15 seconds with 41 queries by YEKTAWEB 4643